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Abstract: In the framework of the EU project EQuATox, a first international proficiency test (PT) on
the detection and quantification of botulinum neurotoxins (BoNT) was conducted. Sample materials
included BoNT serotypes A, B and E spiked into buffer, milk, meat extract and serum. Different
methods were applied by the participants combining different principles of detection, identification
and quantification. Based on qualitative assays, 95% of all results reported were correct. Successful
strategies for BoNT detection were based on a combination of complementary immunological,
MS-based and functional methods or on suitable functional in vivo/in vitro approaches (mouse
bioassay, hemidiaphragm assay and Endopep-MS assay). Quantification of BoNT/A, BoNT/B
and BoNT/E was performed by 48% of participating laboratories. It turned out that precise
quantification of BoNT was difficult, resulting in a substantial scatter of quantitative data. This
was especially true for results obtained by the mouse bioassay which is currently considered as
“gold standard” for BoNT detection. The results clearly demonstrate the urgent need for certified
BoNT reference materials and the development of methods replacing animal testing. In this
context, the BoNT PT provided the valuable information that both the Endopep-MS assay and the
hemidiaphragm assay delivered quantitative results superior to the mouse bioassay.
Keywords: proficiency test; BoNT; reference material; standardized detection
1. Introduction
Botulinum neurotoxins (BoNTs) comprise a family of high molecular weight bacterial toxins
which are produced by the anaerobic Gram-positive bacteria Clostridium (C.) botulinum, C. butyricum
and C. baratii. BoNTs are known as causative agents of the rare, but severe neurological disease
botulism characterized by descending flaccid paralysis including double vision, ptosis, dyspnea,
constipation and/or nausea and in severe cases death by respiratory failure [1]. The disease occurs
in three major forms: Food-borne botulism is caused by ingestion of food contaminated with BoNT.
Wound botulism occurs after uptake of C. botulinum spores into wounds and subsequent germination
with parallel production of BoNT. Finally, infant botulism is caused in babies within their first year of
life by colonization of the intestinal tract and toxin production [1]. While C. botulinum is principally
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able to produce up to four different types of toxins, botulinolysin (a pore-forming toxin), C2 and
C3 toxin (ADP-ribosylating toxins) and the neurotoxin, only the latter one is linked to botulism [2].
BoNTs are remarkable in different ways:
(i) The high variability of BoNTs. The group of BoNTs can be distinguished into seven confirmed
serotypes, A through G. While serotypes A, B, E, and F cause botulism in humans, serotypes C
and D have been attributed to veterinary botulism [3]. The last decade has shown that there is a
previously unrecognized variability among BoNT molecules: the serotypes A, B, E, and F can be
distinguished into more than 40 subtypes based on their amino acid sequence, antibody binding
and functional activity. Depending on the serotype, the sequence variability among subtypes can
reach 36% on amino acid level [4–11]. Additionally, mosaic toxins have been described [12–14].
(ii) Complex formation of BoNTs. In acidic bacterial supernatants the neurotoxins are not found as
pure 150 kDa di-chain toxins, but are associated with non-toxic non-hemagglutinin (NTNHA),
and additionally—depending on serotype and subtype—with up to three different hemagglutinins
(HA17, HA33 and HA70) constituting different high molecular weight progenitor toxin complexes
(PTCs): M-PTC is composed of BoNT plus a corresponding NTNHA forming an interlocked
complex of 290 kDa [15] and is produced by all strains. The L-PTC consisting of BoNT, NTNHA,
HA70, HA17, and HA33 at a stoichiometry of 1:1:3:3:6 resulting in a 760 kDa molecule [16,17]
is found in strains producing serotypes A, B, C, D and G. While the exact mechanism of BoNT
uptake is currently under investigation, it has already been shown that the complex proteins play
a role in stabilizing the toxin during the passage through the gastrointestinal tract (NTNHA) and
in the adsorption process at intestinal epithelia (HA proteins) [15,18–21]. On the genetic level, the
genes encoding for BoNT and the different complex proteins are arranged in a bicistronic gene
cluster comprising an ntnha-bont operon and an ha operon (ha`orfX´ cluster; [4]). Apart from this
cluster, a second gene cluster is observed, where the genes encoding HA are replaced by three
genes encoding OrfX proteins of yet unknown expression and function (ha´orfX` cluster [4,19]).
(iii) The exquisite toxicity of BoNTs. The BoNTs constitute the most poisonous toxins known today.
Lethal amounts of crystalline BoNT/A L-PTC in humans are estimated from primate studies to
be 1 µg/kg body weight when taken orally, 10 ng/kg by inhalation and 1 ng/kg intravenously or
intramuscularly [22].
(iv) The highly specific mechanism of intoxication. After oral uptake, BoNTs reach the neuromuscular
junction of cholinergic neurons. As members of the family of A–B protein toxins the BoNT
molecules consist of a 100 kDa B-domain called heavy chain (HC) and an enzymatically active
50 kDa A-domain called light chain (LC) which are covalently linked by a disulfide bridge [23].
The HC confers receptor binding and cellular uptake, while the LC acts as zinc-dependent
metalloprotease that specifically cleaves proteins of the soluble N-ethylmaleimide-sensitive factor
attachment protein receptor (SNARE) complex which mediates the release of acetylcholine
from synaptic vesicles. The SNARE complex is formed by the assembly of the proteins
synaptosome-associated protein of 25 kDa (SNAP-25), syntaxin and vesicle-associated membrane
protein (VAMP)/synaptobrevin [24]. While BoNT/A, C and E cleave at different sites of SNAP-25,
BoNT/C also targets syntaxin. BoNT/B, D, F and G cleave at distinct sites of VAMP. After cleavage
of any of the above-mentioned SNARE proteins, the formation of the SNARE complex is inhibited,
resulting in the blockage of neurotransmitter release. This leads to the classical paralytic symptoms
of botulism [25,26].
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BoNTs are typical dual-use substances: as the most toxic substances known to man and as the
causative agents of botulism the toxins attracted attention of those intending criminal, terroristic
and military misuse. Exemplarily, the Japanese Aum cult tried to disperse C. botulinum culture
supernatants in Tokyo on different occasions between 1990 and 1995 [27]. Additionally, BoNT
was included in different weapons programs during World War II and later [28]. Based on its
history, BoNT is a prohibited substance under the Biological Weapons Convention (BWC) and
classified as select agent category A by the Centers for Disease Control and Prevention (CDC,
Atlanta, GA, USA). On the positive side, based on the highly specific biological action in vivo,
BoNTs are being applied medically as long-acting peripheral muscle relaxant with annual revenues
of more than $2.5 billion. Mainly serotype A and to a limited extent serotype B have developed
into an indispensable pharmaceutical agent and are currently approved for the treatment of more
than 20 neurological and non-neurological diseases, among them strabismus, dystonia, spasticity,
hyperhidrosis and migraine [29]. Additionally, among the general public BoNT has become famous
for its application in aesthetic medicine [30].
Considering the different aspects of security, health and consumer protection as well as medical
application the rapid detection, precise identification and accurate potency determination of BoNT
is important. Generally, the different fields of BoNT research have quite contrary requirements
for diagnostic approaches: while in the case of botulism diagnostics from clinical, food and
environmental samples the focus is on the reliable detection of all serotypes and subtypes—including
known and unknown subtypes—in complex matrices, highly purified pharmacological products
require the precise and statistically valid potency determination [31]. Different functional,
immunological, spectrometric and molecular methods have been developed to cope with the different
technical demands [31,32]. Still, in many application fields the classical mouse bioassay (MBA)
introduced in the 1920s [33] is considered as a “gold standard method” since it has an exquisite
detection limit (down to a few pg toxin per mouse), measures all steps of BoNT’s mode of action
and is able to detect all functionally active BoNT variants; therefore it is currently included in official
methods and national guidelines (e.g., AOAC Official Method 977.26 or the German Standard DIN
10102). Due to serious ethical concerns and a number of experimental disadvantages, replacement
methods have been introduced, among them the mouse phrenic nerve hemidiaphragm (MPN)
assay as an ex vivo method [34,35]. In this type of assay an explanted preparation of the phrenic
nerve connected with the hemidiaphragm muscle is electrically stimulated and the resulting muscle
twitches are measured. Upon addition of BoNT, the time required to decrease the amplitude
to 50% of the starting value is measured as paralytic half-time which is directly proportional to
the dose of BoNT applied [36,37]. Additionally, in vitro activity assays measuring the catalytic
endopeptidase activity of the LC of BoNT have been developed. Basically, endopeptidase assays
display the serotype-specific proteolytic cleavage of SNARE proteins in conjunction with technically
different read-outs, e.g., mass spectrometric (Endopep-MS assay [38]) or immunological detection
of cleavage products (Endopep-ELISA [39,40]). In order to apply the enzymatic assay on real sample
materials, an immunoaffinity enrichment step is usually applied, where the toxin is captured from the
matrix using antibody-coated magnetic microbeads prior to performing the endopeptidase reaction,
resulting in assay sensitivities similar or better to those of the MBA [31,41]. Endopeptidase assays
usually detect the LC activity only. Therefore in different approaches HC-specific antibodies or
alternatively receptor binding have been applied for toxin extraction and combined with detection
of cleaved substrates [42–44]. Independent of the aforementioned approaches different cell-based
assays have been developed which are currently in use for precise potency determination of highly
pure pharmacological preparations and for BoNT inhibitor screening [45,46]. Their applicability for
routine diagnostic purposes has to be evaluated in the future.
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In contrast to in vivo, ex vivo or in vitro activity assays, pure immunological approaches
detect only the presence of the toxin, not its activity. Nonetheless, sandwich enzyme-linked
immunosorbent assays (ELISAs) are by far the most commonly employed in vitro method for BoNT
detection due to their generally high sensitivity, their simplicity, short assay times and robust assay
performance [31,47–50]. However, quality and validity of obtained data strictly depend on the
quality and combination of the antibodies used. The same is true for immunochromatographic
lateral flow assays (LFA) which are hand-held devices based on a sandwich ELISA performed on
paper strips. Usually, they have restricted sensitivity compared to conventional ELISAs and are
more prone to matrix interferences [31]. A number of interesting new developments have been
published in recent years which aim at miniaturizing BoNT detection on the protein or functional
level, among them microarray or biosensor applications, centrifugal microfluidic disk platforms and
portable devices [51–55].
In light of the range of technical approaches, different analytical tools, sample preparation
strategies and assay protocols used in expert laboratories, any comparison of experimental results is
generally difficult. Additionally, no certified reference material is available, so that expert laboratories
currently use either in-house purified BoNT standards or different commercial products of variable
quality. Though different technologies are available in expert laboratories, no proficiency testing (PT)
schemes or ring trials on dedicated techniques are available to identify good analytical strategies
for the analysis of real samples. To the best of our knowledge, only one international exercise was
previously organized that focused on highly pure pharmaceutical-grade BoNT preparations and
specifically addressed potency testing by MBA [56]. With respect to the toxin-producing organism, an
international exercise addressed the detection and typing of BoNT-producing Clostridia by real-time
polymerase chain reaction [57].
Against this background, the current work has been undertaken in the framework of the
EU-project EQuATox (Establishment of quality assurance for the detection of biological toxins of
potential bioterrorism risk [58]) funded under the European Community’s Seventh Framework
Programme to provide an overview and evaluation of existing methods for detection, identification
and quantification of BoNTs on the protein level from real sample materials. In planning an
appropriate exercise, it had to be considered that the current PT was the very first international
activity testing the laboratories’ diagnostic capabilities, so it had to cover a broad range of potential
technical approaches and capabilities. Along this line, the very first international exercise on BoNT
detection and quantification was a “confidence building exercise” offering the possibility to discuss
on potential difficulties and limitations with experts from different countries.
To this end, a PT scheme was designed in line with internationally accepted standards which
comprised 13 test samples containing highly pure, recombinantly expressed BoNT/A, B or E [59]
spiked into buffer, milk, meat extract and serum in a concentration range of 0.5–1000 ng/mL. Stability
and homogeneity was tested according to Thompson et al. and ISO/IEC 17043:2012 [60,61]. For
participating laboratories, the task was to qualitatively detect BoNT-containing samples—either with
or without serotyping—by any technical approach available in the individual laboratory and, if
possible, to quantify the toxin using own in-house reference materials. Here we provide an overview
of qualitative and quantitative results obtained by 23 international expert laboratories from the health,
food and security sector, among them 18 laboratories from EU countries. The results set a basis for
further steps in quality assurance and highlight next priorities in the process of harmonization and
standardization of analytical approaches.
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2. Results and Discussion
2.1. Preparation of the BoNT Proficiency Test
To set up a proper PT test plan, 13 samples were selected for further preparatory analysis taking
into account the following:
(i) The samples were planned to comprise the most important BoNT serotypes pathogenic to humans,
i.e., BoNT/A, BoNT/B and BoNT/E, to test the laboratories’ ability to detect and to differentiate
the different neurotoxins (serotyping). BoNT/F was not considered further as PT material in this
very first PT due to the rareness of natural BoNT/F cases and concerns regarding the stability
of recombinant BoNT/F material. From all the different subtypes of serotypes described so far,
subtypes BoNT/A1, BoNT/B1 and BoNT/E1 were chosen as representative subtypes and used in
this study (abbreviated BoNT/A, B and E throughout this manuscript). Additionally, the 150 kDa
neurotoxins as smallest, but fully functional and well defined entity representing the causative
agent of botulism were used in this first PT. The purity of activated recombinant BoNT/A, BoNT/B
and BoNT/E was determined to beě99% for BoNT/A,ě96% for BoNT/B andě93% for BoNT/E,
respectively (for details see [59]). To test for serotyping capabilities, BoNT/A, BoNT/B and
BoNT/E were included as samples in the PT at an intermediate concentration (10 ng/mL) in 0.1%
BSA/PBS (Table 1).
(ii) The samples needed to be detectable with a range of different techniques, as the PT was open
with respect to the methods applied by the participants. The expectation of a technically open PT
was to obtain information on best analytical practices. To this end, four different concentrations of
purified BoNT/A spiked into buffer containing a stabilizing protein (BSA) were selected: a very
high (1000 ng/mL), a high (100 ng/mL), an intermediate (10 ng/mL) and a moderate (0.5 ng/mL)
concentration of recombinantly expressed, highly purified BoNT/A in 0.1% BSA/PBS (Table 1).
(iii) In order to analyze the influence of complex matrices on the detection of BoNT, the intermediate
concentration of BoNT/A (10 ng/mL) was spiked into human serum, semi-skimmed milk and a
particle-free, sterile extract of minced meat. Both food matrices (semi-skimmed milk and meat
extract) were also spiked with the high concentration (100 ng/mL) of BoNT/A, assuming that in
food poisoning the toxin concentration would be higher.
(iv) Finally, a complex sample was set up comprising both BoNT/A and BoNT/B at equal
concentrations (5 ng/mL each) in 0.1% BSA/PBS. This sample mimicked naturally occurring
C. botulinum strains that produce two or three different BoNTs [62].
Table 1. Proficiency test (PT) test plan.
Samples Selected as Potential PT Samples for Further Stability Testing PT Sample Number
1 1000 ng/mL of BoNT/A in 0.1% BSA/PBS S12
2 100 ng/mL of BoNT/A in 0.1% BSA/PBS S7
3 10 ng/mL of BoNT/A in 0.1% BSA/PBS S2
4 0.5 ng/mL of BoNT/A in 0.1% BSA/PBS S9
5 100 ng/mL of BoNT/A in semi-skimmed milk S13
6 10 ng/mL of BoNT/A in semi-skimmed milk S10
7 100 ng/mL of BoNT/A in meat extract S5
8 10 ng/mL of BoNT/A in meat extract S1
9 10 ng/mL of BoNT/A in human serum S11
10 5 ng/mL of BoNT/A and 5 ng/mL of BoNT/B in 0.1% BSA/PBS S8
11 10 ng/mL of BoNT/B in 0.1% BSA/PBS S6
12 10 ng/mL of BoNT/E in 0.1% BSA/PBS S4
13 0.1% BSA/PBS S3
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The potential PT samples as depicted in Table 1 were further analyzed by stability testing.
According to Thompson et al. and ISO/IEC 17043:2012, samples have to be sufficiently stable during
the predefined testing period which was set to four weeks by the PT organizer [60,61]. Stability
testing was performed by sandwich ELISAs specifically detecting BoNT/A, BoNT/B or BoNT/E,
respectively. Corresponding standard curves of the ELISAs used for the three analytes are depicted
in Figure 1.
For precise quantification, all BoNT-containing samples were diluted to a concentration close to
the EC50 value which is the point of highest precision in measurement (EC50[BoNT/A] = 0.12 ng/mL;
EC50[BoNT/B] = 0.37 ng/mL; EC50[BoNT/E] = 1.56 ng/mL; Figure 1). In order to demonstrate
sample stability during the PT test period, 10 aliquots of each sample S1 to S13 were prepared and
analyzed for stability: five aliquots were stored for four weeks at´80 ˝C, and five aliquots were stored
for four weeks at 4 ˝C for comparison. All sample sets were analyzed simultaneously on a single
day by the different BoNT ELISAs corresponding to the serotype contained in the respective sample.
As indicated in Figure 2, experimental results generally showed a suitable stability of all samples S1
to S13 at 4 ˝C over a period of four weeks. This result was confirmed statistically by Dunnett’s test
which showed no significant deviation in concentrations under these two storage conditions (p > 0.05;
not shown).
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Figure 1. Sandwich enzyme-linked immunosorbent assays (ELISAs) specifically detecting BoNT/A,
BoNT/B or BoNT/E. The ELISAs were performed as described in the Experimental Section and were
used to perform the stability and homogeneity studies as well as for determination of the assigned
concentrations of the PT samples. The curves show results of three to five independent measurements
performed in duplicate using the recombinant toxins produced in [59]. EC50 values indicating the
half-maximum concentration that ca b measured by the given ELISAs are in icated by a gray circl .
Based on the stability study, samples S1 to S13 were selected as suitable PT samples. For the
actual PT, 40 aliquots of each sample S1 to S13 were prepared as before. Of these, 10 aliquots of
each sample were randomly selected for homogeneity testing. Homog neity of each test materi l
was assessed according to Thompson et al. [60] and ISO/IEC 17043:2012 [61] by employing the
corresponding sandwich ELISAs and deducing the concentration of the 10 test portions of each
sample. Figure 3 graphically displays the results of the homogeneity tests in which 10 aliquots of
each sample were quantified twice in duplicate by ELISA. At first glance sufficient homogeneity was
observed. In some cases the variance between the duplicates was larger than the variance between
the two experiments or the 10 replicates. Statistically, Cochran tests showed no outlying variance for
all samples at a significance level of 0.05 (not show ).
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Figure 2. Stability of PT samples as measured by BoNT-specific sandwich ELISAs. All 13 samples
were either stored at ´80 ˝C or 4 ˝C for four weeks (4w ´80 ˝C or 4w 4 ˝C). Concentrations in
samples S1, S2, S4, S5, S7, S8, S9, S10, S11, S12 and S13 were quantitated by BoNT/A-specific ELISA,
samples S6 and S8 by BoNT/B-specific ELISA and S4 by BoNT/E-specific ELISA; error bars indicate
the standard deviations obtained for five randomly selected sample replicates per storage condition.
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Figure 3. Homogeneity study. Ten randomly selected test portions of each sample (S1–S13)
were analyzed by BoNT/A-, BoNT/B- or BoNT/E-specific ELISA, respectively, in two independent
experiments (depicted in red and blue), each performed in duplicate. The mean concentration of each
duplicate ˘ standard deviation (error bars) was plotte against the 10 replicates of each sample.
Though the highly purified recombinant BoNT/A, BoNT/B and BoNT/E preparations,
thoroughly characterized by Weisemann et al. [59] and used here to spike PT samples, represent
well-defined, qualified materials, they are still no certified reference materials. According to
Thompson et al., in this situation it is necessary to determine the protein concentration experimentally
after spiking the purified toxins into the buffer or matrix [60]. This provides the “nominal
concentration” of the samples as opposed to the “theoretical concentration” that is the known spiked
4942
Toxins 2015, 7, 4935–4966
concentration, assuming there are no losses during sample preparation, no matrix effects or other
disturbing factors.
To this end, the experimental data obtained in the homogeneity testing for the 10 randomly
selected aliquots were used to determine the nominal concentration of the PT samples. For each
randomly selected aliquot one dilution close to the EC50 value of the corresponding ELISA for
BoNT/A, BoNT/B or BoNT/E, respectively, was chosen to calculate the nominal concentrations. The
dilutions were measured in duplicate in two independent experiments. The calculated concentrations
of the ten replicates of each sample measured in two experiments were statistically analyzed, and
estimates of the nominal concentrations were obtained with the robust algorithm according to ISO
5725-5:1998 [63]. The robust means of the nominal concentrations were adopted as “assigned values”
for the evaluation of the quantitative PT results reported by the participants. Table 2 summarizes
the theoretical concentration for each sample, the robust estimate of the mean nominal concentration
based on the experiments performed in the organizer’s laboratory as well as the robust estimate of
the standard deviation of the nominal concentrations. Additionally, for the subsequent quantitative
analysis of PT results reported by the participants, the standard deviation for proficiency assessment
σp was calculated as given in the Experimental Section.
Table 2. Proficiency test: sample identity and statistics.
Sample Matrix Serotype/Measurand c(theoretical)* (ng/mL)
c(nominal)
** (ng/mL)
σ(rob)
(ng/mL)
σp
(ng/mL)
S1 Meat extract BoNT/A 10 10.5 1.4 2.68
S2 0.1% BSA/PBS BoNT/A 10 9.9 1.3 2.52
S3 0.1% BSA/PBS – – – – –
S4 0.1% BSA/PBS BoNT/E 10 10.9 0.9 2.77
S5 Meat extract BoNT/A 100 108.0 10.0 27.60
S6 0.1% BSA/PBS BoNT/B 10 9.0 0.9 2.29
S7 0.1% BSA/PBS BoNT/A 100 100.0 9.0 25.50
S8/A 0.1% BSA/PBS BoNT/A 5 4.7 0.3 1.21
S8/B 0.1% BSA/PBS BoNT/B 5 4.5 0.5 1.15
S9 0.1% BSA/PBS BoNT/A 0.5 0.5 0.1 0.13
S10 Milk BoNT/A 10 10.3 0.8 2.64
S11 Serum BoNT/A 10 9.8 0.3 2.51
S12 0.1% BSA/PBS BoNT/A 1000 1001.0 69.0 255.00
S13 Milk BoNT/A 100 112.0 13.0 28.50
* The “theoretical concentration” was the known concentration of BoNT/A, BoNT/B or BoNT/E that was
spiked into the different matrices; ** Robust estimates of mean nominal concentrations as determined
experimentally by the organizing laboratory by ELISA for BoNT/A, BoNT/B or BoNT/E, respectively.
Adopted as “assigned values” for the evaluation of the quantitative PT results; σ(rob): robust estimate of
the standard deviation of the nominal concentrations; σp: standard deviation for proficiency assessment.
Determination of the nominal concentrations of the 13 samples concluded the preparatory
experimental part of the BoNT PT. With respect to shipment of active toxin-containing samples and
depending on the destination of the shipment, different individual authorizations were required
and obtained by the national authorities of the participating countries, e.g., clearance certificates
and import or export permits. The actual shipment was realized using a dedicated shipper (World
Courier, Berlin, Germany) as security transport: the transport of toxins as a dangerous goods
shipment followed the classification toxic class 6.1, packaging group PGI (P652), UN3172. The
material was packed in IATA/ADR-approved 4GU boxes (Bio-Bottles, Alex Breuer GmbH, Cologne,
Germany), and the dispatch of samples from the organizer’s laboratory was done by a certified
shipping agent. The samples were transported in Bio-Bottles securely locked in 20 kg steel containers
equipped with temperature loggers and cooling devices and were tracked throughout the shipment.
Two months before the actual shipment of samples, the interested laboratories obtained an
official announcement letter including a nomination form and information on objectives of the PT, the
test design, the potential sample materials and measurands, a timeline for the PT, basic information
on reporting and analysis as well as comments on the requirements and regulations to be obeyed.
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Deadline to deliver results was announced to be four weeks after shipment of samples. All in all,
23 expert laboratories from 14 countries worldwide actively took part in the exercise and received
1 mL of samples S1 to S13. All samples reached their destination within three days at the latest.
The electronically transmitted temperature logging files indicated that all packages arrived at their
destinations at temperatures below 7 ˝C. The participants confirmed that all samples arrived cooled
and in a good condition.
In order to re-confirm sample stability, the organizer’s laboratory measured once again the
concentration in all samples in one randomly selected sample set four weeks after sample shipment
(not shown). The concentrations determined in the post stability test were compared to the nominal
concentrations determined before sending samples to PT participants in the homogeneity study and
confirmed the findings of the pre PT stability studies, i.e., that all samples were sufficiently stable
during the period of the BoNT PT.
2.2. Results of the BoNT Proficiency Test
Since one major goal of the BoNT PT was to define good analytical strategies, the PT was
open with respect to the methods applied by the PT participants. The participants were asked
to deliver their results both qualitatively and/or quantitatively in two technically independent
replicates (including all steps of sample preparation) per method applied, using a dedicated Excel
reporting file. Additionally, since laboratories were completely free to combine different methods,
analytical tools and approaches, they were asked to fill in a mandatory summary report summarizing
their sample-specific conclusions in a final result sheet, taking into account different results that
might have been obtained by applying different methods. One challenge in this first international PT
was the restricted sample volume provided (1 mL), considering that in real botulism cases often the
sample material—especially from clinical specimens—is restricted. So if a laboratory was planning
to apply both qualitative and quantitative analysis or to combine different technical approaches, the
volume per analysis had to be carefully planned. Qualitative and quantitative results reported by the
PT participants were summarized in anonymized form and will be discussed in the next two sections.
Any information on how many assays and exactly which assays were used by each laboratory was
considered of potential dual-use-interest and therefore is not given here.
2.2.1. Qualitative Results of the BoNT Proficiency Test
A variety of methods were applied in the BoNT PT, combining different principles of detection,
identification and quantification. Qualitative results were assessed according to the degree of trueness
of the participant’s assignments and color and number codes were used to indicate the assessment.
For analysis and visualization of results, the qualitative results reported by the participants were
color-coded and—when comparing individual methods—additionally number-coded according to
the following legend:
(1) correct positive (1), correct negative (´1), with serotyping
(2) correct positive (1), correct negative (´1), without serotyping
(3) false positive (10), false negative (´10)
(4) one of two reported results false positive (4.5) or false negative (´4.5)
(5) No response or not analyzed
Qualitative results were submitted by 21 out of 23 participants; five participants used different
technical approaches and reported results obtained by different techniques individually while the
majority of all participating laboratories used preferentially a single technology to work on the
13 samples. Figure 4 displays an overview of all results reported in the mandatory summary and
shows that, based on the assessment of qualitative results reported, 95% of all results reported were
correct, corresponding to the majority of results given in dark green.
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The high percentage of qualitatively correct results can be taken as an indication of a successfully
conducted exercise, considering the fact that the PT was the first international one on BoNT detection.
Each horizontal row in Figure 4 represents the summarized results of one participating laboratory.
Twenty participants reported qualitative results including serotyping, and one participant reported
presence of BoNT without serotyping (light green, Figure 4). Three participants did not summarize
their results in the mandatory summary report; therefore they are given as a white row in Figure 4.
The figure shows that 10 out of 23 laboratories provided correct results for all 13 samples, not taking
into account their serotyping capabilities.
In order to extract relevant technical information from the qualitative measurements performed
in the BoNT PT, the results reported after using different methods were further analyzed according
to different parameters:
(i) based on sample identity comparing results provided for corresponding samples (e.g., comparison
of results submitted for a given concentration of BoNT in buffer, milk, meat extract and serum;
comparison of results given for different concentrations or different serotypes);
(ii) based on the comparison of different technological approaches (i.e., comparison of different
approaches like mouse bioassay, MS-based approaches or different ELISA assays displayed against
each other).
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Figure 4. Summarized results reported by all 23 participating laboratories for samples S1–S13.
The individual laboratories—each indicated in a horizontal row—were asked to summarize their
experimental results for the 13 samples obtained by different methods. Qualitative results reported
by the participants were color-coded according to the following legend: “correct, with serotyping
of BoNT” (green) and “correct, without serotyping of BoNT” (light green); “false positive or false
negative” (red); “one of two reported results false positive or false negative” (yellow); “no response
or not analyzed” (white). Participating laboratories marked by an asterisk (‹) delivered qualitatively
correct results for all 13 samples, not taking into account serotyping of samples. Three participants did
not summarize their results in the mandatory summa y report; ther fore th y a given as white row.
This analysis is displayed in Figures 5–10 where each row indicates a qualitative result reported
by a single method; several laboratories reported more than one method, therefore more than 23 rows
are displayed in Figures 5–10.
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Figure 5 shows the comparison of qualitative results reported after using different methods
for samples containing different concentrations of BoNT/A (from 1001 ng/mL to 0.5 ng/mL) in
buffer. Based on the results reported for the very high concentration of BoNT/A in buffer (S12,
1001 ng/mL), 88.9% of results submitted were correct and 11.1% insufficient. For the sample with
the high concentration of BoNT/A (S7, 100 ng/mL) all results were correct, for the intermediate
concentration (S2, 9.9 ng/mL) 92.0% of results were correct and 8.0% insufficient, while for the
moderate concentration of BoNT/A (0.5 ng/mL) 76.9% of results reported were correct and 23.1%
insufficient. For the results submitted for the negative control sample (Figure 5b) containing buffer
only, 96.0% of all results obtained by different methods were correct, 4.0% were partly correct and
none was insufficient. So overall around 92%–100% of all results were correct when BoNT/A was
present at high concentrations, while the percentage of correct results decreased to 76.9% when
moderate concentrations were present. Considering that clinical or food samples often contain
low ng/mL to pg/mL amounts of toxin, this basic result indicates that there is room for technical
improvement to detect moderate and low concentrations of BoNT.
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Figure 5. Qualitative results obtained for samples containing BoNT/A in different concentrations in
buffered solution. (a) BoNT/A concentrations present in samples S12, S7, S2 and S9 are indicated in
the table header; (b) Results obtained for negative control sample. Each row indicates a qualitative
result reported after using a particular method; several laboratories reported more tha one method.
Qualitative results reported by he participants w re colo -coded s indicated above, with green
corresponding to “correct positive (1) or correct negative (´1)”; yellow corresponding to “one of two
reported results false positive (4.5) or false negative (´4.5)”; red corresponding to “false positive (10)
or false negative (´10)” and white “no response or not analyzed”. Indicated below is the percentage
of qualitative results reported for the given samples as “BoNT/A” (a) or “BoNT absent” (b).
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In Figure 6 the comparison is shown of qualitative results reported after using different methods
for samples containing either about 100 ng/mL of BoNT/A (a) or 10 ng/mL of BoNT/A (b) in
different matrices. Overall, the matrices offered posed no significant difficulties in analysis. It can
be seen that 84.0 to 100% of results were correct for both concentrations, when toxin-spiked buffer,
meat extract or milk were analyzed. Unexpectedly, the percentage of correct results dropped to 80.0%
when toxin-spiked serum was analyzed. Taking into account that serum is the standard clinical matrix
measured in suspicious botulism cases, the results offer potential for technical improvement.
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Figure 6. Qualitative results obtained for samples containing BoNT/A in different complex matrices.
(a) Results obtained for samples containing ~100 ng/mL of BoNT/A spiked into complex matrices or
into buffer; (b) Results obtaine f r samples contai ing ~10 ng/mL of BoNT/A spiked into complex
matrices or into buffer. Each row indicates a qualitative result reported after using a particular
method; several laboratories reported more than one method. Qualitative results reported by the
participants were color-coded as described in Figure 5. Indicated below is the percentage of qualitative
results reported for the given s mpl s as “BoNT/A”.
Finally, Figure 7 displays qualitative results reported for different serotypes (BoNT/A, B and E)
present at a concentration of around 10 ng/mL. In the direct comparison of samples containing one
serotype in buffer, BoNT/A, B or E resulted in 92.0%, 88.0% or 95.5% correct results, respectively
4947
Toxins 2015, 7, 4935–4966
(Figure 7a). When sample S8 containing both BoNT/A and BoNT/B in equimolar concentrations
(around 5 ng/mL) was analyzed, it turned out that 87.5% of results were correct for one serotype,
BoNT/A, while only 75.0% of results were correct for the second serotype, BoNT/B (Figure 7b).
The results suggest that a mixture of serotypes is more difficult to analyze than samples containing
one serotype, indicating another starting point for method improvement.
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Figure 7. Qualitative results obtained for samples containing different BoNT serotypes. (a) Results
obtained for samples containing different BoNT serotypes at ~10 ng/mL; (b) Results obtained for
sample S8 containing two serotypes (BoNT/A and BoNT/B) in equal concentrations (~5 ng/mL each).
Each row indicates a qualitative result reported after using a particular method; several laboratories
reported more than one method. Qualitative results reported by the participants were color-coded
as described in Figure 5. Indicated below is the percentage of qualitative results reported for S2 as
“BoNT/A”, S6 as “BoNT/B”, S4 as “BoNT/E” and S8 as “BoNT/A” and “BoNT/B”.
Regarding the differe technical app oaches used by the 23 participating laboratories, a variety
of methods were applied, combining different principles of detection and identification. An overview
of qualitative results obtained by the different methods applied is given in Figure 8 for results
reported as measurand “BoNT/A”, in Figure 9 for measurand “BoNT/B” and in Figure 10 for
measurand “BoNT/E”, respectively.
Sev ral laboratori s used immunological detection methods: four different ELISA approaches,
two different LFA approaches and several combinations of different immunoassays were reported.
As shown in Figures 8 and 10 all four ELISA approaches resulted in correct results for BoNT/A
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and BoNT/E on all 13 samples, while for BoNT/B flaws occurred using ELISA 1 and ELISA 4
on single samples (Figure 9). In contrast, ELISA 2 and ELISA 3 delivered correct results for all
samples and all three analytes. Surprisingly, one of the LFAs (LFA 2) was able to identify correctly all
samples for the measured serotypes BoNT/A, BoNT/B and BoNT/E, including the sample with the
moderate concentration (S9, 0.5 ng/mL of BoNT/A), thus showing an exquisite detection limit of this
on-site detection test compared to other LFAs with detection limits in the range of 5–50 ng/mL [64].
With respect to the immunological strategies applied in the PT, selected successful approaches are
presented in more detail in a separate publication in this special issue of Toxins [65].
Two different LC-MS/MS approaches were used either on all samples or on selected, highly
concentrated samples S5 (108 ng/mL of BoNT/A in meat extract), S7 (100 ng/mL in buffer) and
S12 (1001 ng/mL of BoNT/A in buffer). Different sample preparation strategies were applied
and combined with tryptic digest followed by LC-MS/MS analysis on different instruments. The
approaches were successful in identifying several BoNT/A1-specific peptides from the LC and HC in
samples S5, S7 and S12 that allow for unambiguous identification of the toxin including its subtype
(Figure 8 and data not shown). Further technical adaptions, e.g., immunoaffinity enrichment of toxin,
would be necessary to detect samples containing moderate to low concentrations of toxin.
In terms of functional testing, four different detection principles were applied by different
laboratories: two Endopep-ELISA approaches, five Endopep-MS approaches, one MPN approach
and nine classical MBA approaches (Figures 8–10). Generally, the functional approaches resulted in
good success rates for all samples and serotypes with only limited experimental flaws. Specifically, for
each of the different functional in vitro, ex vivo or in vivo approaches, a number of protocols resulted
in correct results (marked by an asterisk in Figures 8–10). Endopep-ELISA 2 delivered correct results
for all BoNT/A-, B- and E-containing samples except for sample S11 for which a false positive result
was reported (Figure 10). Still, based on its overall performance, this approach was selected for a
more detailed description [65]. Out of the five Endopep-MS approaches, four methods delivered
correct results for all samples and all three analytes (Endopep-MS 1 to Endopep-MS 4). With respect
to MS-based strategies including Endopep-MS protocols applied in the PT, successful approaches
are presented in a separate manuscript in this special issue of Toxins [66]. Similarly good results
were obtained by one laboratory applying an MPN assay, which again delivered qualitatively correct
results for all samples and all three analytes measured. This assay is highlighted in [35].
The classical MBA was applied by nine laboratories, eight of which used the assay to perform
serotyping using different mouse strains and different functionally blocking antibodies. One
laboratory used MBA to determine BoNT-containing samples but did not differentiate serotypes
(therefore the respective results given as MBA 1 appear white in Figures 8–10; the reported data
correspond to Figure 4, first row). Overall, results obtained by MBA were satisfying. Specifically,
four protocols (MBA 4, MBA 6, MBA 7 and MBA 9) delivered correct results for all samples and
analytes tested. In a previous inter-laboratory comparison of pharmaceutical BoNT products it has
been shown that even for MBA as “gold standard method” and the analysis of highly pure BoNT
preparations the results are variable depending on experimental parameters like sample preparation,
the age and strain of mice or other factors [56,67]. After the PT, the feedback from laboratories
performing MBA indicated that the laboratories experienced the restricted sample volume (1 mL)
and the number of samples provided (13) as challenging experimental conditions, while these issues
were generally not seen as problems by the laboratories applying in vitro or ex vivo methods.
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quantitative reporting since they have, accidentally, not been reported qualitatively. 
Immunological methods              
ELISA S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 S13 
Different immunoassays –10 1 –1 –1 1 –1 1 –10 –10 1 –10 1 –10  
Different immunoassays –10 –10 –1 –1 1 –1 1 –10 –10 –10 1 1 1  
Sandwich ELISA 1 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Sandwich ELISA 2 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Sandwich ELISA 1 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Sandwich ELISA 3 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Sandwich ELISA 4  $ 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
LFA                            
Lateral flow immunoassay 1 1 1 4.5 –1 1 10 1 1 –10 –4.5 –10 1 1  
Lateral flow immunoassay 2 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
               
Mass spectrometric methods  
MS/MS                            
LC-MS/MS 1 –10 –10 –1 –1 1 –1 1 –10 –10 –10 –10 1 –10  
LC-MS/MS 2     1  1     1  
               
Functional methods   
Endopep-ELISA (in vitro method)                        
Endopep-ELISA 1 1 1 –1 –1 1 –1 1 1 1 1 –10 –10 –10  
Endopep-ELISA 2 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Endopep-MS (in vitro method)                         
Endopep-MS 1 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Endopep-MS 2 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Endopep-MS 3 1 1 –1  1  1 1 1 1 1 1 1  
Endopep-MS 4 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Endopep-MS 5 1 1 –1 10 1 10 1 1 –10 1 1 –10 1  
MPN (ex vivo method)                            
mouse hemidiaphragm assay 1 1   1  1 1 1 1 1 1 1  
MBA (in vivo method)                            
MBA 1               
MBA 2 1 1 –1 –1 1 –1 1 1 1 1 –10 –10 –10  
MBA 3   –1   –1  1 –10   1   
MBA 4 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
MBA 5 1 1  –1 1 –1 1  1 1 1 1 1  
MBA 6 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
MBA 7  1 –1 –1 1 –1 1 1 1 1 1 1 1  
MBA 8 1 1  –1 1 –1 1 1 1 1 1 1 1  
MBA 9 1 1  1 1 1 1 1 1 1  
Figure 8. Qualitative results reported as “BoNT/A” for all 13 samples displayed by the different
methods used. Samples containing BoNT/A are marked with a black arrow (
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other factors [56,67]. After the PT, the feedback from laboratories performing MBA indicated that the 
laboratories experienced the restricted sample volume (1 mL) and the number of samples provided (13) 
as challenging experimental conditions, while these issues were generally not seen as proble s by the 
laboratories applying in vitro or ex vivo m tho s. 
 
Figure 8. Qualitative results reported as “BoNT/A” for all 13 samples displayed by the 
different methods used. Samples containing BoNT/A are marked with a black arrow (). 
Each row indicates a qualitative result reported after using a particular method; several 
laboratories reported more than one method. Qualitative results reported by the participants 
were color-coded as described in Figure 5. Methods marked by an asterisk () delivered 
correct results for the samples analyzed. $, results have been taken from the laboratory’s 
quantitative reporting since they have, accidentally, not been reported qualitatively. 
Immunological methods              
ELISA S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 S13 
Different immunoassays –10 1 –1 –1 1 –1 1 –10 –10 1 –10 1 –10  
Different immunoassays –10 –10 –1 –1 1 –1 1 –10 –10 –10 1 1 1  
Sandwich ELISA 1 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Sandwich ELISA 2 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Sandwich ELISA 1 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Sandwich ELISA 3 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Sandwich ELISA 4  $ 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
LFA                            
Lateral flow immunoassay 1 1 1 4.5 –1 1 10 1 1 –10 –4.5 –10 1 1  
Lateral flow immunoassay 2 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
               
Mass spectrometric methods  
MS/MS                            
LC-MS/MS 1 –10 –10 –1 –1 1 –1 1 –10 –10 –10 –10 1 –10  
LC-MS/MS 2     1  1     1  
               
Functional methods   
Endopep-ELISA (in vitro method)                        
Endopep-ELISA 1 1 1 –1 –1 1 –1 1 1 1 1 –10 –10 –10  
Endopep-ELISA 2 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Endopep-MS (in vitro method)                         
Endopep-MS 1 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Endopep-MS 2 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Endopep-MS 3 1 1 –1    1 1 1 1 1 1 1  
Endopep-MS 4 1 1 –1 –1  –1 1 1 1 1 1 1 1  
Endopep-MS 5 1 1 –1 10  0 1 1 –10 1 1 –10 1  
MPN (ex vivo method)                            
mouse hemidiaphragm assay 1 1   1  1 1 1 1 1 1 1  
MBA (in vivo method)                            
MBA 1               
MBA 2 1 1 –1 –1 1 –1 1 1 1 1 –10 –10 –10  
MBA 3   –1   –1  1 –10   1   
MBA 4 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
MBA 5 1 1  –1 1 –1 1  1 1 1 1 1  
MBA 6 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
MBA 7  1 –1 –1 1 –1 1 1 1 1 1 1 1  
MBA 8 1 1  –1 1 –1 1 1 1 1 1 1 1  
MBA 9 1 1  1 1 1 1 1 1 1  
. Each row indicates
a qualitative result reported after using a particular method; several laboratories reported more
than one method. Qualitative results reported by the participant were color-coded as described in
Figure 5. Methods marked by an asterisk (‹) delivered correct results for the samples analyzed. $,
results have been taken from t e laboratory’s quantitative reporting sinc they have, accidentally, not
been reported qualitatively.
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Figure 9. Qualitative results reported as “BoNT/B” for all 13 samples displayed by the 
different methods used. Samples containing BoNT/B are marked with a black arrow (). 
Each row indicates a qualitative result reported after using a particular method; several 
laboratories reported more than one method. Qualitative results reported by the participants 
were color-coded as described in Figure 5. Methods marked by an asterisk () delivered 
correct results for the samples analyzed. $, results have been taken from the laboratory’s 
quantitative reporting since they have, accidentally, not been reported qualitatively. 
Immunological methods               
ELISA S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 S13  
Different immunoassays –1 –1 –1 10 –1 1 –1 -10 –1 –1 –1 –1 –1  
Different immunoassays –1 –1 –1 –1 10 1 –1 1 –1 –1 –1 –1 –1  
Sandwich ELISA 1 –1 –1 –1 –1 –1 -10 –1 -10 –1 –1 10 –1 –1  
Sandwich ELISA 2 –1 –1 –1 –1 –1 1 –1 1 –1 –1 –1 –1 –1  
Sandwich ELISA 1 –1 –1 –1 –1 –1 1 –1 1 –1 –1 –1 10 –1  
Sandwich ELISA 3 –1 –1 –1 –1 –1 1 –1 1 –1 –1 –1 –1 –1  
Sandwich ELISA 4  $ –1 –1 –1 –1 –1 1 –1 -1 –1 –1 –1 10 –1  
LFA               
Lateral flow immunoassay 1                            
Lateral flow immunoassay 2 –1 –1 –1 –1 –1 1 –1 1 –1 –1 –1 –1 –1  
               
Mass spectrometric methods  
MS/MS               
LC-MS/MS 1 –1 –1 –1 –1 –1 –10 –1 –10 –1 –1 –1 –1 –1  
LC-MS/MS 2                            
               
Functional methods                
Endopep-ELISA (in vitro method)             
Endopep-ELISA 1 –1 –1 –1 –1 –1 1 –1 1 –1 –1   –1 –1  
Endopep-ELISA 2 –1 –1 –1 –1 –1 1 –1 1 –1 –1   –1 –1  
Endopep-MS (in vitro method)             
Endopep-MS 1 –1 –1 –1 –1 –1 1 –1 1 –1 –1 –1 –1 –1  
Endopep-MS 2 –1 –1 –1 –1 –1 1 –1 1 –1 –1 –1 –1 –1  
Endopep-MS 3           1   1            
Endopep-MS 4 –1 –1 –1 –1 –1 1 –1 1 –1 –1 –1 –1 –1  
Endopep-MS 5 –1 –1 –1 –1 –1 –10 –1 –10 –1 –1 –1 –1 –1  
MPN (ex vivo method)               
mouse hemidiaphragm assay           1   1            
MBA (in vivo method)               
MBA 1                            
MBA 2 –1 –1 –1 –1 –1 1 -1 1 –1 –1 –1 –1 –1  
MBA 3     –1     1   1 –1     –1    
MBA 4 –1 –1 –1 –1 –1 1 –1 1 –1 –1 –1 –1 –1  
MBA 5 –1 –1   –1 –1 1 –1 –10 –1 –1 –1 –1 –1  
MBA 6 –1 –1 –1 –1 –1 1 –1 1 –1 –1 –1 –1 –1  
MBA 7   –1 –1 –1 –1 1 –1 1 –1 –1 –1 –1 –1  
MBA 8 –1 –1   –1 –1 1 –1 –10 –1 –1 –1 –1 –1  
MBA 9           1                
Figure 9. Qualitative results reported as “BoNT/B” for all 13 samples displayed by the different
methods used. Samples containing BoNT/B are marked with a black arrow (
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other factors [56,67]. After the PT, the feedback from laboratories performing MBA indicated that the 
laboratories experienced the restricted sample volume (1 mL) and the number of samples provided (13) 
as challenging experimental conditions, while these issues were generally not seen as problems by the 
laboratories applying in vitro or ex vivo methods. 
 
Figure 8. Qualitative results reported as “BoNT/A” for all 13 samples displayed by the 
different methods used. Samples cont ining BoNT/A are marked with a black arrow (). 
Each row indicates a qualitative result reported after using a particular method; several 
laboratories reported more than one method. Qualitative results reported by the participants 
were color-coded as described in Figure 5. Methods marked by an asterisk () delivered 
correct results for the samples analyzed. $, results have been taken from the laboratory’s 
quantitative reporting since they have, accidentally, not been reported qualitatively. 
Immunological methods              
ELISA S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 S13 
Different immunoassays –10 1 –1 –1 1 –1 1 –10 –10 1 –10 1 –10  
Different immunoassays –10 –10 –1 –1 1 –1 1 –10 –10 –10 1 1 1  
Sandwich ELISA 1 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Sandwich ELISA 2 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Sandwich ELISA 1 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Sandwich ELISA 3 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Sandwich ELISA 4  $ 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
LFA                            
Lateral flow immunoassay 1 1 1 4.5 –1 1 10 1 1 –10 –4.5 –10 1 1  
Lateral flow immunoassay 2 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
               
Mass spectrometric methods  
MS/MS                            
LC-MS/MS 1 –10 –10 –1 –1 1 –1 1 –10 –10 –10 –10 1 –10  
LC-MS/MS 2     1  1     1  
               
Functional methods   
Endopep-ELISA (in vitro method)                        
Endopep-ELISA 1 1 1 –1 –1 1 –1 1 1 1 1 –10 –10 –10  
Endopep-ELISA 2 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Endopep-MS (in vitro method)                         
Endopep-MS 1 1 1 –1 –1 1 –1 1 1 1  1   
Endopep-MS 2 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Endopep-MS 3 1 1 –1  1  1 1 1 1 1 1 1  
Endopep-MS 4 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Endopep-MS 5 1 1 –1 10 1 10 1 1 –10 1 1 –10 1  
MPN (ex vivo method)                            
mouse hemidiaphragm assay 1 1   1  1 1 1 1 1 1 1  
MBA (in vivo method)                            
MBA 1               
MBA 2 1 1 –1 –1 1 –1 1 1 1 1 –10 –10 –10  
MBA 3   –1   –1  1 –10   1   
MBA 4 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
MBA 5 1 1  –1 1 –1 1  1 1 1 1 1  
MBA 6 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
MBA 7  1 –1 –1 1 –1 1 1 1 1 1 1 1  
MBA 8 1 1  –1 1 –1 1 1 1 1 1 1 1  
MBA 9 1 1  1 1 1 1 1 1 1  
. Each row indicates
a qualitative result reported after using a particular method; several laboratories reported more
than one method. Qualitative results reported by the participants were color-coded as described in
Figure 5. M thods marked by an sterisk (‹) delivered correct results for the samples analyzed. $,
results have been taken from t e laboratory’s quantitative reporting sinc they have, accidentally, not
been reported qualitatively.
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Figure 10. Qualitative results reported as “BoNT/E” for all 13 samples displayed by the 
different methods used. Samples containing BoNT/E are marked with a black arrow (). 
Each row indicates a qualitative result reported after using a particular method; several 
laboratories reported more than one method. Qualitative results reported by the participants 
were color-coded as described in Figure 5. Methods marked by an asterisk () delivered 
correct results for the samples analyzed. $, results have been taken from the laboratory’s 
quantitative reporting since they have, accidentally, not been reported qualitatively. 
Based on the qualitative PT results reported by the 23 participating laboratories, good analytical 
practices can now be derived: to this end, the different technical approaches applied were grouped 
together according to their detection principle and statistically analyzed, thus providing an overview of 
success rates obtained for the different detection principles on all 13 samples. This analysis is useful for 
drawing some general conclusions on the methods applied, while it is important to keep in mind that 
different analytical protocols and tools have been used and that for each detection principle successful 
individual strategies have been identified in the PT (Figures 8–10). Additionally, one should keep in 
mind that the methods were applied by a variable number of laboratories, so that statistics should not be 
overestimated (e.g., the MPN assay was applied by one laboratory only, whereas the MBA was applied 
by nine participants, and ELISA and Endopep-MS were used by at least five laboratories). Table 3 
provides an overview of success rates obtained for the different detection principles on all 13 samples. 
Immunological methods               
ELISA S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 S13  
Different immunoassays                            
Different immunoassays 10 –1 –1 1 10 –1 –1 –1 –1 –1 –1 10 –1  
Sandwich-ELISA 1 –1 –1 –1 1 –1 –1 –1 –1 –1 –1 –1 –1 –1  
Sandwich-ELISA 2 –1 –1 –1 1 –1 –1 –1 –1 –1 –1 –1 –1 –1  
Sandwich-ELISA 1 –1 –1 –1 1 –1 –1 –1 –1 –1 –1 –1 –1 –1  
Sandwich-ELISA 3 –1 –1 –1 1 –1 –1 –1 –1 –1 –1 –1 –1 –1  
Sandwich-ELISA 4  $ –1 –1 –1 1 –1 –1 –1 –1 –1 –1 –1 –1 –1  
LFA               
Lateral flow immunoassay 1                            
Lateral flow immunoassay 2 –1 –1 –1 1 –1 –1 –1 –1 –1 –1 –1 –1 –1  
               
Mass spectrometric methods  
MS/MS               
LC-MS/MS 1 –1 –1 –1 –10 –1 –1 –1 –1 –1 –1 –1 –1 10  
LC-MS/MS 2                            
               
Functional methods                
Endopep ELISA (in vitro method)             
Endopep-ELISA 1                            
Endopep-ELISA 2 –1 –1 –1 1 –1 –1 –1 –1 –1 –1 10 –1 –1  
Endopep MS (in vitro method)                          
Endopep-MS 1 –1 –1 –1 1 –1 –1 –1 –1 –1 –1 –1 –1 –1  
Endopep-MS 2 –1 –1 –1 1 –1 –1 –1 –1 –1 –1 –1 –1 –1  
Endopep-MS 3       1                    
Endopep-MS 4 –1 –1 –1 1 –1 –1 –1 –1 –1 –1 –1 –1 –1  
Endopep-MS 5 –1 –1 –1 1 –1 –1 –1 –1 –1 –1 –1 –1 –1  
MPN (ex vivo method)               
mouse hemidiaphragm assay       1                    
MBA (in vivo method)               
MBA 1                            
MBA 2 –1 –1 –1 1 –1 –1 –1 –1 –1 –1 –1 –1 –1  
MBA 3     –1     –1   –1 –1     –1    
MBA 4 –1 –1 –1 1 –1 –1 –1 –1 –1 –1 –1 –1 –1  
MBA 5 –1 –1   1 –1 –1 –1 –1 –1 –1 –1 –1 –1  
MBA 6 –1 –1 –1 1 –1 –1 –1 –1 –1 –1 –1 –1 –1  
MBA 7   –1 –1 1 –1 –1 –1 –1 –1 –1 –1 –1 –1  
MBA 8 –1 –1   1 –1 –1 –1 10 –1 –1 –1 –1 –1  
MBA 9       1                    
Figure 10. Qualitative results reported as “BoNT/E” for all 13 samples displayed by the different
methods used. Samples containing BoNT/E are marked with a black arrow (
Toxins 2015, 7 18 
 
 
other factors [56,67]. After the PT, the feedback from laboratories performing MBA indicated that the 
laboratories experienced the restricted sample volume (1 mL) and the number of samples provided (13) 
as challenging experimental conditions, while these issues were generally not seen as problems by the 
laboratories applying in vitro or ex vivo methods. 
 
Figure 8. Qualitative results reported as “BoNT/A” for all 13 samples displayed by the 
different methods used. Samples cont ining BoNT/A are marked with a black arrow (). 
Each row indicates a qualitative result reported after using a particular method; several 
laboratories reported more than one method. Qualitative results reported by the participants 
were color-coded as described in Figure 5. Methods marked by an asterisk () delivered 
correct results for the samples analyzed. $, results have been taken from the laboratory’s 
quantitative reporting since they have, accidentally, not been reported qualitatively. 
Immunological methods              
ELISA S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 S13 
Different immunoassays –10 1 –1 –1 1 –1 1 –10 –10 1 –10 1 –10  
Different immunoassays –10 –10 –1 –1 1 –1 1 –10 –10 –10 1 1 1  
Sandwich ELISA 1 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Sandwich ELISA 2 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Sandwich ELISA 1 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Sandwich ELISA 3 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Sandwich ELISA 4  $ 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
LFA                            
Lateral flow immunoassay 1 1 1 4.5 –1 1 10 1 1 –10 –4.5 –10 1 1  
Lateral flow immunoassay 2 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
               
Mass spectrometric methods  
MS/MS                            
LC-MS/MS 1 –10 –10 –1 –1 1 –1 1 –10 –10 –10 –10 1 –10  
LC-MS/MS 2     1  1     1  
               
Functional methods   
Endopep-ELISA (in vitro method)                        
Endopep-ELISA 1 1 1 –1 –1 1 –1 1 1 1 1 –10 –10 –10  
Endopep-ELISA 2 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Endopep-MS (in vitro method)                         
Endopep-MS 1 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Endopep-MS 2 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Endopep-MS 3 1 1 –1  1  1 1 1 1 1 1 1  
Endopep-MS 4 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
Endopep-MS 5 1 1 –1 10 1 10 1 1 –10 1 1 –10 1  
MPN (ex vivo method)                            
mouse hemidiaphragm assay 1 1   1   1 1 1 1 1 1  
MBA (in vivo method)                            
MBA 1               
MBA 2 1 1 –1 –1 1 –1 1 1 1 1 –10 –10 –10  
MBA 3   –1   –1  1 –10   1   
MBA 4 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
MBA 5 1 1  –1 1 –1 1  1 1 1 1 1  
MBA 6 1 1 –1 –1 1 –1 1 1 1 1 1 1 1  
MBA 7  1 –1 –1 1 –1 1 1 1 1 1 1 1  
MBA 8 1 1  –1 1 –1 1 1 1 1 1 1 1  
MBA 9 1 1  1 1 1 1 1 1 1  
. Each row indicates
a qualitative result reported after using a particular method; several laboratories reported more
th n one method. Qualitative results reported by the participants were colo -coded as described in
Figure 5. Methods marked by an asterisk (‹) delivered correct results for the samples analyzed. $,
results have been taken from t e laboratory’s quantitative reporting sinc they have, accidentally, not
been reported qualitatively.
Based on the qualitative PT results reported by the 23 participating laboratories, good analytical
practices can now be derived: to this end, the different technical approaches applied were grouped
together according to their detection principle and statistically analyzed, thus providing an overview
of success rates obtained for the different detection pri ciples on all 13 samples. Th s analysis is
useful for drawing some general conclusions on the methods applied, while it is important t keep
in mind that different analytical protocols and tools have been used and that for each detection
principle successful individual strategies have been identified in the PT (Figures 8–10). Additionally,
one should keep in mind that the methods were applied by a variable number of laboratories, so
that statistics should not be overestimated (e.g., the MPN assay was applied by one laboratory only,
whereas the MBA was appli d by ine participants, and ELISA and En opep-MS were used by at
least five laboratories). Table 3 provides an overview of success rates obtained for the different
detection principles on all 13 samples. Generally, the success rate of the methods applied ranged
from 80% to 100%. For the two immunological methods ELISA and LFA the success rate for correct
results was 93.3% and 90.4%, respectively, which is in the range of results reported in a previous
study: In a national ring trial five samples—four toxin-positive ones and a negative one—were
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distributed to 57 laboratories to evaluate a set of four BoNT/A-, B-, E-, and F-specific ELISA kits,
resulting in 86% correct results for all five samples [68]. In the current BoNT PT the lowest percentage
of correct results (80%) was reached when using LC-MS/MS methods, presumably because of the
lower sensitivity of this method compared to others. The in vitro functional method Endopep-ELISA
showed a success rate (93.6%) similar to that of the classical sandwich ELISA (93.3%). Interestingly,
for qualitative analysis the other two functional approaches, the Endopep-MS assay (97.3%) and the
MPN assay (100%), turned out to be as successful as the in vivo functional method, the classical
MBA (97.6%). Therefore, it can be concluded that both methods represent an excellent alternative
for BoNT detection and serotyping compared to the classical MBA. Against the background that the
MPN assay was applied by one laboratory only, future exercises with more participants applying
this method have to show if this good result can be reproduced. While the Endopep-MS assay as an
in vitro method does not require animal tissue at all, the MPN assay still uses animal tissues, but fully
replaces animal experiments and requires fewer animals than an MBA. Depending on the tools used
for toxin enrichment, the Endopep-MS assay is able to represent the catalytic and the receptor-binding
activity of BoNT only [38]. In contrast, the MPN assay has the advantage of detecting all steps of
BoNT activity—surface receptor binding, internalization of toxin into the neuron, translocation of
catalytically active LC into the cytoplasm, proteolytic cleavage of SNARE proteins plus blockade
of neurotransmitter release; hence inactivated, non-dangerous BoNT is not measured, in contrast
to some of the in vitro methods [35]. So depending on the application field—either diagnostics
of suspected botulism samples or potency determination of BoNT pharmaceuticals—some method
might be technically more appropriate than another one.
With respect to good analytical practices, the PT showed that laboratories’ applying either
a combination of complementary in vitro approaches (immunological, MS-based plus functional
methods) or an appropriate individual functional approach (either MBA or MPN or Endopep-MS
assay) delivered superior results. This information will be crucial in the future to develop
recommended operating procedures and optimized workflows for the analysis of toxin-containing
samples that will be supported internationally.
Table 3. Qualitative results of methods used for BoNT serotyping: overview of success rates obtained
after using different methods for all samples. *
Method Total Number of Results Number of Laboratories Correct Results % Total %
ELISA 312 7
correct positive 24.4
93.3correct negative 68.9
LFA 52 2
correct positive 38.5
90.4correct negative 51.9
LC-MS/MS 55 2
correct positive 10.9
80.0correct negative 69.1
Endopep-ELISA 63 2
correct positive 34.9
93.6correct negative 58.7
Endopep-MS 222 5
correct positive 27.5
97.3correct negative 69.8
MPN 13 1
correct positive 100.0
100.0correct negative 0.0
MBA 330 9
correct positive 26.1
97.6correct negative 71.5
* Detailed classification of success rates for the different methods applied for BoNT serotyping. For each
method the total number of results reported per method is indicated, the number of laboratories applying an
individual method and the percentage of correct positive or correct negative results.
2.2.2. Quantitative Results of the BoNT Proficiency Test
Independent of the qualitative reporting, the participating laboratories were asked to perform
quantification of BoNT/A, BoNT/B or BoNT/E in the 13 samples and to report the results of
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two independent measurements in a dedicated Excel reporting file. Again, for quantification any
method established and validated in the laboratories was admitted; if the laboratories planned to
use different methods for quantification, they were asked to submit results in separate quantitative
reporting sheets. In this context, some basic questions were asked regarding the scope of assay
validation performed prior to the PT (e.g., detection limit of the method, coefficients of variation
and measurement uncertainty) and the reference material used. The quantitative measurements
reported by the participants were—as far as possible—evaluated statistically according to the
recommendations by Thompson et al. [60] and Algorithm A of the international standard ISO
13528:2005 “Statistical methods for use in proficiency testing by inter-laboratory comparisons” [69].
Quantification of BoNT/A, BoNT/B and/or BoNT/E in the 13 samples was performed by 11 of
23 participating laboratories (48%). In order to assess and visualize quantitative results, z-scores were
calculated according to the equation
z “ x´ xa
σp
with x denoting the results reported by the participants, xa the assigned concentration value
determined by the organizing laboratory and σp the standard deviation for proficiency assessment,
respectively (Table 2). z-scores (in the context of PTs) quantify the difference between an individual
single or mean result and the assigned value in units of the standard deviation for proficiency
assessment. This transformation is known as standardization; the standardized data set has a mean
of zero (0) and a standard deviation (and variance) of one (1) if xa and σp are the respective statistics
of the empirical distribution of the data considered. A z-score of zero indicates an unbiased result
with respect to the assigned value, a z-score of 1 is one standard deviation for proficiency assessment
above the assigned value, a z-score of ´1 is one standard deviation for proficiency assessment below
the assigned value and so on. Provided that the data points are realizations of normally distributed
random variables with mean xa and standard deviation σp (i.e., x ~N(xa, σp2), this is the model to
which the results reported are compared), the z-scores represent realizations of random variables of
the standard normal distribution (i.e., z ~N(0, 1)), where about 95% of z-scores will fall between ´2
and +2 (the sign “´” or “+” of the score indicates a negative or positive deviation, respectively).
According to Thompson et al. [60], scores in this range are commonly designated “acceptable” or
“satisfactory”. Scores in the ranges ´2 to ´3 and +2 to +3 would be expected about once in 20, and
scores in this class are sometimes designated “questionable”. A score outside the range from ´3 to
+3 would be very unusual and is taken to indicate that the cause of the event should be investigated
and remedied, and Thompson et al. [60] suggest the phrase “requiring action” for such results.
In the PT it turned out that precise quantification of BoNT/A, BoNT/B and/or BoNT/E was
difficult, resulting in a substantial scatter of quantitative data. Exemplarily, the quantitative results
provided by the participants for samples S12, S7, S2 and S9, containing different concentrations of
BoNT/A in buffer starting from 1001 ng/mL to 0.5 ng/mL, are visualized in Figure 11. Normal
probability plots of z-scores are displayed for all z-scores obtained (Figure 11a) and zoomed into
the region between z = ´4 and +4 (Figure 11b). z-scores of normally distributed concentration
values with sample statistics xa and σp2 would lie along a straight line with slope 1 in these plots.
Normal probability plots are used to display both the dispersion of a data set and the deviation of the
empirical distribution from statistical normality. As can be seen in Figure 11, many of the quantitative
data approximately follow the normal distribution of the model x ~N(xa, σp2), but some values are
far off. Additionally, overall a positive bias of measured results from the assigned concentrations
was observed, since the positive deviations of data reported were much wider than the negative
deviations. This effect was seen independently of the methods used for quantification. The zoom-in
in Figure 11b shows that four to six methods resulted in z-scores between ´3 and +3, indicating
that there is room for technical improvement. Still, taking into account that different reference
materials were used in different laboratories, the results offer a sound basis for further steps in
quality assurance.
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In order to interpret the quantitative data obtained in the BoNT PT, the participants were asked
to provide information on their BoNT standards used in the PT: standards from up to six different
sources were used depending on the BoNT serotype (six different BoNT/A standards, four different
BoNT/B standards and three BoNT/E standards, among them commercially available preparations
and in-house materials of different quality). To understand basic factors influencing the quantitative
data, the organizing laboratory compared two of the ELISAs applied by different participants and
two different 150 kDa BoNT/A standards used in the PT. For the selected tools and assays, the
results showed that the use of different ELISAs had no significant influence on the quantification of
BoNT-containing samples, whereas the use of different reference standards clearly did: differences by
a factor of two or more were obtained for the PT samples (data not shown). Based on this limited data
that awaits further investigation, we speculate that the heterogeneity in quantification of BoNT/A,
BoNT/B and BoNT/E in the PT samples is most likely due to the different reference materials used.
Thus, quantification of BoNT can only be improved if a common certified reference standard becomes
available—this is considered to be a priority aim for future research.
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Figure 11. Normal probability plots of z-scores for quantification of BoNT/A. (a) Standard normal
quantiles were plotted against the z-scores to visualize if scores (representing concentrations reported)
were normally distributed. The analysis was done by considering all methods used to quantify the
indicated samples. Each dot corresponds to one method used by one laboratory. The number of dots
does not necessarily reflect the number of laboratories since several laboratories used ore than one
method to quantif the samples. (b) The magnified plot shows the data from (a) zoomed int z-scores
from ´4 to +4.
In order to evaluate the different methods used in the PT for quantification of all samples,
the accordance of methods was assessed for the different technical approaches. Figure 12 shows
the z-score means (points and figures) and their standard deviations (error bars span mean ˘ SD)
as computed from the z-scores. The z-score means offer a guide to assess the mean closeness
of a method to the assigned concentration if applied by a number of laboratories to a number
of samples, and the corresponding standard deviation measures the variation of the z-scores
among the respective samples and laboratories. For z(BoNT/A) sufficient and comparable numbers
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of cases were obtained to draw some general conclusions (Figure 12): The z-score means vary from
1.5 to 31.4. Endopep-ELISA and Endopep-MS assay showed an acceptable mean closeness (absolute
z-score < 2.5) with good accordance between the z-scores means among samples and laboratories (low
standard deviation).
The in vivo method MBA showed the highest z-score mean (31.4) compared to the other methods,
with less accordance between the z-scores among samples and laboratories (high standard deviation).
The immunological methods, ELISA and LFA, as well as the MPN assay delivered intermediate
results between the in vitro functional methods and the in vivo functional method.
The comparison of the different methods applied for quantification of BoNT/A showed the
lowest accordance between the z-scores among samples and laboratories for the in vivo method
MBA. This result might not be surprising, since previous work has already shown difficulties in
quantification of BoNT activity using this in vivo assay [56]. Apart from the influence of different
experimental factors on the actual performance of the MBA, the low accordance of data probably also
reflects a more general difficulty in BoNT quantification which is related to the different units that can
be used: quantification can either be based on (i) protein content, expressed e.g., in ng/mL, and/or
based on (ii) biological activity, measured, e.g., in mouse LD50/mL. Laboratories using MBA or/and
Endopep-MS assay for quantification measured the 13 PT samples in LD50/mL and calculated back
into protein content based on literature data or own validation studies. However, in this calculation
attention has to be paid on (i) the purity and specific activity of the reference material; (ii) the
proportion of denatured, truncated, single chain or otherwise non-functional toxin in the reference
material; (iii) the serotype and the subtype of toxin analyzed and, finally, (iv) the occurrence of
toxin (pure di-chain toxin, M-PTC, L-PTC). Most of these factors are unknown for the in-house or
commercially available reference materials used. Strictly speaking, the conversion of activity into
protein content can only be applied for one defined preparation of BoNT where the above-mentioned
factors are known. Also, the type of assay used to determine activity in vivo, ex vivo or in vitro plays
an important role, as it is already known that different functional read-outs might result in different
activities [6,68,70,71]. Also, species-specific effects on toxicity have been described and should be
taken into consideration [72,73].
It cannot be ruled out that the low accordance between z-scores among samples and laboratories
detected by MBA (Figure 12) could be due to a partial loss of functional activity of the toxins used
to spike PT samples rather than true assay variation. In the stability study (Figure 2), quantitative
ELISA were used to demonstrate sample stability based on (i) the high throughput of the method
(130 samples had to be precisely quantitated on a single day); (ii) the high precision of the method;
and finally (iii) the legal restraints in EU to sacrifice >13,000 mice for activity measurement to serve
a diagnostic PT [74]. Against this background, we explicitly did not ask for determining functional
activity, but to report on the samples’ protein content in ng/mL. In case of significant instabilities of
the recombinant materials used to spike PT samples we would have expected that the 17 laboratories
using different functional approaches (MBA, MPN assay, Endopep-MS, Endopep-ELISA) would have
reported more diverse quantitative data. This was, however, not the case except for those laboratories
using MBA. In the absence of a final proof, we think on the basis of available data that the stability of
the recombinant material is satisfactory. This finding would be in line with results demonstrated for
the pharmaceutical product incobotulinumtoxin A (Merz Pharma, Frankfurt am Main, Germany)
comprising only the pure 150 kDa BoNT/A as active ingredient which displays a shelf-life of
3–4 years at room temperature [75]. In any case, on the way towards certified reference materials,
future work has to address the formulation of toxins as well as more extensive stability studies.
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Figure 12. Accordance of methods used for quantification of BoNT/A in the BoNT PT. z-score means
(points and figures) ˘ standard deviation as computed from the z-scores for methods specifically
detecting BoNT/A. The analysis was done by considering all samples analyzed in the PT with the
in icated methods. For the different methods applied in the PT, the following numbers of z-scores
from single values reported were included: ELISA (140), LFA (38), Endopep-ELISA (20), Endopep-MS
(20), MPN assay (20) and MBA (28).
When comparing different assay formats among each other, the molecular variability within
the BoNT family with more than 40 known subtypes has to be considered [62,76]. The challenge of
BoNT subtypes has not yet been addressed in this very first international BoNT PT, but surely will
be an issue in future exercises. The large variability poses a challenge to genetic and immunological
detection approaches. Basically, assays which rely on antibodies either for immunoenrichment or
detection have to be validated on all known subtypes or sequence variants unless the exact antigenic
epitope is known. However, such comprehensive analysis has been difficult to conduct due to the
restrict d access to all known subtypes. Also, the results obtained in this exercise are valid for the
selected subtypes used to spike samples and have to be reviewed in future exercises on a broader
panel of subtypes. On the other hand, for certain functional assays like MBA or MPN assay sequence
variation does not impair detection of functional activity as long as the BoNT-subtype/variant is
effective in the underlying species (e.g., human, mouse, rat). In an ideal situation, functional methods
wo ld deliver qualitatively identical results—quantitation of ctivity, howev r, can result in diff rent
units of activities which are method dependent. A more extensive discussion on this point can be
found in Weisemann et al. [59] in this special issue of Toxins.
Generally, for the different application fields—from the health, food and security sectors to
pharmaceutical industry—the specific biological activity of BoNT is the most informative measure
on the quality of a given BoNT preparation; however, it is the most difficult one to standard ze.
In contrast, measurement of precise protein content as sum of active and inactive BoNT can be
better standardized, e.g., by amino acid analysis [77]. With respect to future efforts to improve
BoNT quantification in international laboratories, precise and accurate BoNT quantification requires
appropriate certified reference materials with defined specific biological activity AND protein content
that would be available to ex ert l boratories worldwide. T se reference materials should be
characterized with a broad range of different analytical methods, considering and extending the work
that has been performed in the EQuATox project.
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3. Experimental Section
3.1. Preparation of PT Samples
The BoNT preparations used in this PT to spike buffer and complex matrices are described in
more detail in [59]. Briefly, as prototypic neurotoxins full-length BoNT/A1, BoNT/B1 and BoNT/E1
were produced by recombinant expression in K12 E. coli strains and isolated by fused affinity tags
which were removed due to thrombin recognition site. To obtain maximum activity, posttranslational
proteolytic activation of single chain BoNT was performed by hydrolyzing a thrombin recognition
motif inserted into the sequence of the loop region connecting LC and HC. From the comprehensive
characterization of the recombinant BoNTs produced it was concluded that BoNT/A1 was 99.9% pure
and between 97% and 99% activated into LC and HC; BoNT/B1 was 96% pure and 100% activated;
and finally BoNT/E1 was 93% pure and between 92 and 95% activated [59].
Protein concentration was determined by validated amino acid analysis [77]. The biological
activity expressed as LD50 was determined by mouse bioassay (BoNT/A1, 1.43 ˆ 108 LD50/mg;
BoNT/B1, 4.95 ˆ 107 LD50/mg; BoNT/E1, 4.08 ˆ 107 LD50/mg) [59]. Throughout this manuscript,
the recombinant BoNT preparations are abbreviated BoNT/A, BoNT/B and BoNT/E, keeping in
mind that subtype 1 has been used.
As complex food matrices ultra-high temperature (UHT) semi-skimmed milk and minced meat
were purchased from a local retail store. Milk was opened under sterile conditions and spiked with
a defined amount of BoNT as indicated in Table 1. A particle-free meat extract was prepared by
extracting 30 g of minced meat from pork and beef (1:1) with 270 mL of 0.1% BSA/PBS buffer (pH
6). The meat was removed by centrifugation and the supernatant was autoclaved, filtrated and
spiked with a defined amount of BoNT as indicated in Table 1. The spiked liquid food matrices
were analyzed and quantitated for their BoNT concentration by sandwich ELISA without any further
sample preparation. Human serum was selected as typical clinical sample in cases of suspected
botulism and was collected from anonymous donors without demographic information, pooled prior
to use and shown to be free of BoNT/A, B and E by sandwich ELISA. All three complex matrices as
well as buffer (0.1% BSA/PBS) were spiked with defined amounts of BoNT/A, BoNT/B or BoNT/E
as indicated in Table 1, and the amount of spiked toxin was quantified by sandwich ELISA specific
for the different serotypes (Section 3.3).
3.2. Stability and Homogeneity Testing
In order to demonstrate sample stability during the PT test period (set to four weeks), 10 aliquots
of each sample S1 to S13 were prepared by spiking of the matrices with BoNT/A, BoNT/B or BoNT/E
as indicated in Table 1 and used prior to the actual PT for stability testing: five aliquots were stored
for four weeks at ´80 ˝C, and five aliquots were stored for four weeks at 4 ˝C for comparison
(total number of aliquots: 130). After storage at the indicated condition the samples were frozen
at ´80 ˝C until analysis. All sample sets were analyzed simultaneously on a single day by different
BoNT ELISAs corresponding to the serotype contained in a sample: an ELISA detecting BoNT/A for
samples S1, S2, S4, S5, S7, S8, S9, S10, S11, S12 and S13; a BoNT/B-specific ELISA for samples S6 and
S8 and an ELISA specific for BoNT/E (S4).
BoNT/A, BoNT/B and BoNT/E ELISAs were performed as described in Section 3.3. For
analysis, all BoNT/A-containing samples were diluted to a concentration of 0.1 ng/mL which is
in the linear range of the respective ELISA close to the EC50 value. Along the same line, for the
BoNT/B-ELISA samples containing BoNT/B were diluted to a concentration of 0.3 ng/mL before
analysis, and for analysis by BoNT/E-ELISA the sample containing BoNT/E was diluted to a
concentration of 2 ng/mL.
For statistical analysis of ELISA results, outlying values were identified by Grubbs tests
(R package “outliers [78,79]”) and excluded from the fitting of linear models with storage conditions
4958
Toxins 2015, 7, 4935–4966
as fixed effects and post hoc Dunnett tests with storage condition 4 weeks at ´80 ˝C as control group,
using SYSTAT 13 (SYSTAT Software Inc., Chicago, IL, USA).
For homogeneity testing, 40 aliquots of each sample S1 to S13 were prepared as before, and
10 randomly selected aliquots were used for homogeneity testing. Homogeneity of each test
material was assessed according to Thompson et al. [60] and ISO/IEC 17043:2012 [61] on the basis
of absorbance values at 450 nm obtained by sandwich ELISA and the deduced concentrations on the
10 test portions of each sample. The 10 randomly selected test aliquots of each sample were analyzed
in duplicate in two independent experiments using BoNT/A-, BoNT/B- or BoNT/E-specific ELISA,
respectively. The ELISAs were performed as described in Section 3.3.
The statistical analysis of ELISA data identified one obvious outlier which was excluded from
the analysis according to Thompson et al. [60], consisting of Cochran tests to assess homogeneity
of variances and the estimation of the variance components related to sampling and analytical
variance, respectively. As the experiment was more sophisticated than that described in [60],
factorial linear mixed models were set up to fit the data and to provide (robust) estimates of
the sampling standard deviations and the analytical standard deviations, respectively, using the R
package “robustlmm” [80]. Confidence intervals of the sampling variances were obtained by fitting
the same models with SYSTAT 13 and assessed according to Recommendation 8. Furthermore, the
analytical results of the homogeneity study were evaluated by the robust algorithm according to ISO
5725-5:1998 [63] to compute the nominal concentrations (using R package “metrology” [81]) which
were finally used as assigned values in the calculation of z-scores.
Additionally, for the quantitative analysis of PT results reported by the participants, the standard
deviation for proficiency assessment σp was calculated assuming a normal variate 0.95 confidence
interval of [xa ´ 0.5xa; xa + 0.5xa] (corresponding to a reproducibility limit of 0.5xa), i.e., σp =
0.5xa/1.96 = 0.255xa. As there are no “true” values or certified reference materials available, this
was the choice made on the basis of the rule that inter-laboratory reproducibility limits are very often
about twice the repeatability limits. The latter was assumed to be about 25% of the concentration, as
was supported later by the experience in this PT (Table 2).
3.3. Amplified Sandwich ELISAs Specific for BoNT/A, B and E
Sandwich ELISAs specifically detecting BoNT/A, B or E were performed as described
elsewhere [48,50,82] using mAb and pAb indicated in Table 4. BoNT/E-specific antibodies were
generated similar to BoNT/A- and BoNT/B-specific reagents described in [48]. Briefly, Nunc
MaxiSorp microtiter plates (Thermo Scientific, Brunswick, Germany) were coated with primary mAb
(10 µg/mL) in 50 µL of PBS overnight at 4 ˝C and blocked with casein buffer (Senova, Jena, Germany)
for 1 h at room temperature. After washing, 50 µL of toxin-containing solution was added in serial
dilutions starting from 500 ng/mL to 6.4 pg/mL in assay buffer (PBS, 0.1% BSA; Sigma-Aldrich,
Munich, Germany) as standard curve and incubated for 2 h at room temperature. The sandwich
ELISA was developed by incubation with biotin-labelled secondary antibody diluted in casein buffer
(1 h, room temperature), followed by a washing step and detection with Streptavidin-PolyHRP40
conjugate (0.5 ng/mL, Senova, Jena, Germany). After a washing step color reaction was developed
by adding substrate 3,31,5,51-tetramethylbenzidine (TMB; SeramunBlau slow, Seramun Diagnostika,
Heidesee, Germany). Reaction was stopped by 0.25 M sulfuric acid.
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Table 4. Sandwich ELISAs specifically detecting BoNT/A, B or E. *
Antigen Primary Ab, Name(Specificity) Description [Ref.]
Secondary Ab,
Name (Specificity) Description [Ref.]
BoNT/A A1688 (HN) mAb [48,50] HcA78 (HC) mAb [82]
BoNT/B B279 (LC) mAb [48,50] Botulism antitoxinBehring (LC, HC)
pAb: horse-anti
BoNT/A, B, E,
F(ab)2 fragments;
Novartis, CH
BoNT/E KE97 (LC, HC) purified pAb fromrabbit [65] E136 (HN) mAb [65]
* The domain recognized by the different antibodies is indicated with LC = light chain, HN = N-terminal
domain (HN) and C-terminal domain (HC) of the heavy chain (HC) of BoNT.
3.4. Statistical Analysis and Data Visualization
Qualitative responses (categories “0”, “1” and “n.a.”, indicating “absent”, “present” and “not
analyzed/not available”, respectively) were compared to the correct answers by simple algorithms
coding auxiliary variables representing the “success”: 1 for correct positive, ´1 for correct negative,
10 for false positive, and ´10 for false negative. The latter coding of single responses leads to mean
values 4.5 and ´4.5 if one of two reported results is false positive or false negative, respectively. For
dichotomic grouping (correct/false) it was sufficient to use codes 1 and 0, respectively. On the basis
of these categorical auxiliary variables, the success rates were obtained by frequency tabulation or
by computing the means of the (0/1)-coded auxiliary variables grouped by the categories of interest
(e.g., grouped by method). The resulting data tables were exported from SYSTAT to Excelr and
color-coded by conditional color formatting of each cell of the auxiliary variables.
Quantitative measurements reported by the participants were statistically evaluated
according to the recommendations of Thompson et al. [60] and Algorithm A of the international
standard ISO 13528:2005 [69] which is identical to the robust algorithm according to ISO
5725-5:1998 [45]. Robust algorithms of the R package “metrology” were used to compute the assigned
concentrations. z-scores were obtained on the basis of these assigned values (Table 2) and the
respective standard deviations for proficiency assessment (Section 2.1). Normal probability plots of
the z-scores were produced by commercial software (SYSTAT 13) in order to visualize the empirical
distributions of the results reported, as compared to the model implicitly set as normal distribution
with mean xa and variance σp2, i.e., x ~N(xa, σp2). Assessment of the accordance of methods was
based on the arithmetic means of the individual z-scores as shown in Figure 12.
4. Conclusions
The aim of the BoNT PT conducted in the framework of the EQuATox project was to provide
an overview and evaluation of existing methods for screening, detection and identification of
BoNTs pathogenic to human among 23 participating laboratories from EU-28 and beyond. The
exercise was the very first of its kind to explore qualitative and quantitative detection capabilities
in international expert laboratories from the health, food and security sector. The 13 samples
included BoNT/A, B and E in buffer, food and clinical matrices and were offered at restricted
volume (1 mL), taking into account that in real botulism cases the available material is usually
limited. The results highlight the status quo of detection capabilities which is—with 95% qualitatively
correct results reported—generally good. In detail, potential for further technical improvement
was identified with respect to: (i) sensitivity of methods; (ii) specificity of methods (serotyping)
and (iii) matrix interference. Samples containing BoNT at low concentrations in pure solution or
in matrix as well as serotype distinction were the most challenging tasks. A variety of methods
were used by the participants, combining different detection principles. Generally, for all different
technical approaches used by the participants, individual strategies were identified that delivered
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qualitatively correct results (as sum of good tools, good protocols, good experimental performance,
so overall good proficiency). Two different sandwich-ELISAs and one LFA were identified that
provided correct results for all samples and all serotypes down to the sub-ng/mL level, therefore
these methods represent useful screening techniques and are presented in more detail together
with a successful Endopep-ELISA approach in a separate manuscript in this issue of Toxins [65].
One LC-MS/MS method delivered correct results for toxin-containing samples in the ng/mL range
and was suitable for the identification of the toxin subtype. As to MS-based strategies including
functional approaches, four successful, highly sensitive Endopep-MS assay protocols were identified,
and selected approaches are presented in a separate manuscript in this special issue of Toxins [66].
With respect to functional testing and in light of the new EU legislation on animal testing [74], there
is an urgent need to replace the mouse bioassay as “gold standard” of BoNT detection. In this
respect, the BoNT PT provided the valuable information that both the Endopep-MS assay [66] and
the MPN assay [35] delivered results qualitatively similar to those of the MBA, but rendered superior
quantitation of BoNT. Also, an Endopep-ELISA approach delivered convincing results, therefore this
method should also be further explored as replacement method [65].
Generally, with respect to good analytical practices identified in the PT, it turned out that
laboratories applying either a combination of complementary in vitro approaches (immunological,
MS-based plus functional methods) or an appropriate individual functional approach (either MBA
or MPN or Endopep-MS assay) delivered superior results. Based on this information, future efforts
will address the development of recommended operating procedures and optimized workflows for
the analysis of BoNT-containing samples—ideally this would be done in the context of a consolidated
international EQuATox network. In technical terms, it has to be considered that the different methods
vary with respect to trueness, precision, sensitivity, specificity and discriminative power, and that
for all methods a dedicated validation is necessary to obtain reliable results. Still, the information
generated in this PT will be very helpful for the decision of which methods can be used and
combined in order to get preliminary, confirmed or unambiguous results for a BoNT-containing
sample. Depending on the specific requirements of the application field (public health, forensic
analysis or pharmaceutical industry), different methods or combinations of techniques might be
selected as appropriate. To this end, the different method-papers in this special issue of Toxins provide
contact points for laboratories seeking experimental advice.
In terms of quantification of BoNT, a substantial scatter of quantitative data was observed in
the PT. Most methods provided results in the correct order of magnitude, but some z-scores were
out of the range of ´3 and +3, indicating that there is significant room for technical improvement.
Comparative experiments in the organizing laboratory led to the conclusion that this scattering is very
likely due to the different reference materials used in expert laboratories. Therefore, future technical
improvement in quantification of BoNT will require appropriate certified reference materials with
defined specific biological activity AND protein content that would be available to international
expert laboratories. These reference materials should be useful for advances in quality assurance in
all different sectors of BoNT research, the health, food and security sectors as well as pharmaceutical
industries. In this context, the BoNT PT has provided a solid basis and a starting point for future
advancement. Future challenges will address more difficult technical tasks such as detection and
quantification of different/rare BoNT sero- and subtypes, pure di-chain toxin versus different complex
forms and the analysis of more complex real sample matrices. To this end, the international
discussions will have to focus on the general requirements regarding the level of harmonization or
standardization that is useful and necessary in the different application fields to meet public health,
clinical laboratory and forensic needs supporting efficient management decisions.
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